Spanish 
Chinese 
Russian 
German 
French 
Japanese 
Portuguese 
Hindi Case Report
Long-term Survival of Large Cell Neuroendocrine Lung Carcinoma with Bony Metastases: A Case of Immunoprotectivity?
Deborah Paul, Sarah Lander, Anna R Cooper* and Wakenda K TylerDepartment of Orthopaedics and Rehabilitation, University of Rochester Medical Center, 601 Elmwood Ave, Box 665 Rochester, NY 14642, USA
- *Corresponding Author:
- Anna Cooper
Department of Orthopaedics and Rehabilitation
University of Rochester Medical Center
601 Elmwood Ave, Box 665, Rochester
NY14642, USA
Tel: 5852755168
E-mail: anna_cooper@urmc.rochester.edu
Received Date: April 06, 2016; Accepted Date: April 14, 2016; Published Date: April 21, 2016
Citation: Paul D, Lander S, Cooper AR, Tyler WK (2016) Long-term Survival of Large Cell Neuroendocrine Lung Carcinoma with Bony Metastases: A Case of Immunoprotectivity? J Orthop Oncol 2: 110. doi:10.4172/2472-016X.1000110
Copyright: © 2016 Paul D, et al. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.
Abstract
Large cell neuroendocrine carcinoma (LCNEC) is a rare, highly malignant neoplasm with a dismal prognosis. The majority of patients will present with metastatic disease with a median overall survival of 6 months for this group. We present a case of metastatic LCNEC to the pelvis with a 10 year survival after tumor resection, radiation, and chemotherapy. We hypothesize that his survival and cancer stability are the result of an immune response brought on by a sub-acute turned chronic wound infection. After adjuvant therapies, he remained disease-free for 4 years until a recurrence in his lung and new metastases to his spine, which were treated with radiation. He remained disease-free for an additional 6 years, during which time, he discovered to have a chronic infection of his right femur with Staphylococcus Lugdunensis. To the best of our knowledge, this is the first long-term survivor of LCNEC with bony metastases.
